GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » EV-to-Revenue

NLS Pharmaceutics (NLS Pharmaceutics) EV-to-Revenue : (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NLS Pharmaceutics's enterprise value is $5.33 Mil. NLS Pharmaceutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil. Therefore, NLS Pharmaceutics's EV-to-Revenue for today is .

The historical rank and industry rank for NLS Pharmaceutics's EV-to-Revenue or its related term are showing as below:

NLSP's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.03
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-17), NLS Pharmaceutics's stock price is $0.1494. NLS Pharmaceutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00. Therefore, NLS Pharmaceutics's PS Ratio for today is .


NLS Pharmaceutics EV-to-Revenue Historical Data

The historical data trend for NLS Pharmaceutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics EV-to-Revenue Chart

NLS Pharmaceutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial - - - - -

NLS Pharmaceutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NLS Pharmaceutics's EV-to-Revenue

For the Biotechnology subindustry, NLS Pharmaceutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NLS Pharmaceutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's EV-to-Revenue falls into.



NLS Pharmaceutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

NLS Pharmaceutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5.325/0
=

NLS Pharmaceutics's current Enterprise Value is $5.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NLS Pharmaceutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NLS Pharmaceutics  (NAS:NLSP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

NLS Pharmaceutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.1494/0
=

NLS Pharmaceutics's share price for today is $0.1494.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NLS Pharmaceutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.